about
Update on human herpesvirus 6 biology, clinical features, and therapyAntiviral therapies on the horizon for influenzaAcyclic nucleoside phosphonates containing a second phosphonate group are potent inhibitors of 6-oxopurine phosphoribosyltransferases and have antimalarial activityRole of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)Inhibition of the Escherichia coli 6-oxopurine phosphoribosyltransferases by nucleoside phosphonates: potential for new antibacterial agentsAza-acyclic nucleoside phosphonates containing a second phosphonate group as inhibitors of the human, Plasmodium falciparum and vivax 6-oxopurine phosphoribosyltransferases and their prodrugs as antimalarial agentsFirst Crystal Structures of Mycobacterium tuberculosis 6-Oxopurine Phosphoribosyltransferase: Complexes with GMP and Pyrophosphate and with Acyclic Nucleoside Phosphonates Whose Prodrugs Have Antituberculosis ActivityThe Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignDifferent mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnetQuantitative analysis of human herpesvirus 6 cell tropism9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeysMarked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agentDifferential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurineMechanism of anti-HIV action of masked alaninyl d4T-MP derivativesMutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonucleaseAntiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.Emerging antiviral strategies to interfere with influenza virus entry.Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine].Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutininAzapropellanes with anti-influenza a virus activity.Interaction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.Acyclic/carbocyclic guanosine analogues as anti-herpesvirus agents.Inhibitory effect of 9-(2-phosphonylmethoxyethyl)adenine on visna virus infection in lambs: a model for in vivo testing of candidate anti-human immunodeficiency virus drugs.Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8.Antiviral therapy for adenovirus infections.Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage.Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics.Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach.Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection.In search of effective anti-HHV-6 agents.Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1Pronounced Inhibition Shift from HIV Reverse Transcriptase to Herpetic DNA Polymerases by Increasing the Flexibility of α-Carboxy Nucleoside Phosphonates.N-acylhydrazone inhibitors of influenza virus PA endonuclease with versatile metal binding modes.Clinical features and treatment of adenovirus infections.Crystal structures and inhibition of Trypanosoma brucei hypoxanthine-guanine phosphoribosyltransferase.Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms.Chelation Motifs Affecting Metal-dependent Viral Enzymes: N'-acylhydrazone Ligands as Dual Target Inhibitors of HIV-1 Integrase and Reverse Transcriptase Ribonuclease H Domain6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.
P50
Q24557543-B96CD645-5CD7-471D-9C63-74580600258BQ26738562-5231D17D-E352-44C9-8EFA-8E356968CC72Q27684093-79E5D51A-C62C-4873-8D2E-69C150E5FD57Q27685318-78A1BA73-BB66-4B1B-8F0F-64154151C4CDQ27685350-7CA03772-6593-42F7-A8F8-B1C01A5289FCQ27696829-B12529B8-AC14-487A-A283-C5E38B85E846Q27700264-D20212D7-0127-4679-92E8-5E41CE453FE3Q28071809-8F22BFE2-D0B5-407B-9FAF-B3347CC4D32FQ28252709-B8C4620E-8C6A-4C16-94FB-80AA03853348Q28293267-0262C101-CDBE-4357-A248-D8FCD86E97E8Q28328373-55B7E59D-0A65-4FC6-9157-FC21441624D9Q28360109-1C729358-8961-4878-ADB1-83BFE11350B1Q28378681-EA54BF16-2711-4C6D-B759-34C57D44E0B4Q28378931-16B8E30F-02E3-41BF-8BEE-B9E0277F8718Q28534627-7740B3C0-1FC3-4AD1-8329-FA4B0FCC72F5Q30231576-4F1D7545-33E7-4D26-BB57-7717EE983431Q30432421-1F4715D0-9EF8-4E15-AC0F-99E0B9929D82Q32084536-4F22EDCE-A700-4145-BE0C-66A5A9EFD5FFQ33826751-E212E308-F54E-4614-8FA0-10BEB8FF1E7BQ33889072-FA7AC173-8B71-431A-AEBD-96A1260B349FQ34162849-6274BCAA-299B-47BB-925D-109684F01401Q34373532-364C1E75-C7A1-4610-9D3A-13CEAA461A7DQ34429807-878CEC24-42E1-473B-AC41-F453D808A150Q34464958-4AE534CE-8741-4EFC-8B27-D673415682B3Q34567467-17A13285-4751-4C80-943D-DAC9F1960393Q34736407-01DD8753-36D6-421B-9678-0CED2A1FADE3Q35212611-E2ED31FD-ABF3-494C-8370-3BC1D5C10A9BQ35960631-F3B58E07-B705-4F60-8EF3-32ACF67B193FQ36164152-38809150-44D3-4959-8F3C-EBF6AD3EF4E9Q36538677-F6D5CCEE-8642-4656-99D7-F25258D099C2Q36727470-19C147A8-DFB7-45B2-93C2-2E33BD445028Q36962978-BDB6FCE0-4DCE-453B-A2CB-B834421EDE38Q36970906-DCC0EE1F-4370-40C8-983E-7F7FF905A023Q37166751-FBB72391-F773-4FF7-876B-6591AAFB6843Q37226671-1D72EBEF-1F45-4787-87A1-DA19FF0B14FAQ37369043-547D6747-4583-467D-9EB2-737526874DA6Q37565121-12C96ADA-C849-470F-B84E-7148A4444571Q37710343-90DCF4D2-3D23-46BB-9DFD-74A5B1A8C0D6Q37880921-F1BB4DA8-A056-4891-9B02-942084014E1CQ38452544-427C878F-6906-42FC-B7EF-DBACE8F25FAB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lieve Naesens
@ast
Lieve Naesens
@br
Lieve Naesens
@co
Lieve Naesens
@da
Lieve Naesens
@de
Lieve Naesens
@en
Lieve Naesens
@es
Lieve Naesens
@fr
Lieve Naesens
@id
Lieve Naesens
@it
type
label
Lieve Naesens
@ast
Lieve Naesens
@br
Lieve Naesens
@co
Lieve Naesens
@da
Lieve Naesens
@de
Lieve Naesens
@en
Lieve Naesens
@es
Lieve Naesens
@fr
Lieve Naesens
@id
Lieve Naesens
@it
prefLabel
Lieve Naesens
@ast
Lieve Naesens
@br
Lieve Naesens
@co
Lieve Naesens
@da
Lieve Naesens
@de
Lieve Naesens
@en
Lieve Naesens
@es
Lieve Naesens
@fr
Lieve Naesens
@id
Lieve Naesens
@it
P106
P21
P31
P496
0000-0001-9742-9302